Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Refractory Granulomatous Lobular Mastitis
NCT07595900Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2026
- Primary completion
- Oct 2028
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in Granulomatous lobular mastitis (GLM), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Inflammatory Remission Rate at 8 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
Granulomatous lobular mastitis (GLM)
Beyond the preview
Go deeper on NCT07595900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595900.